Skip to content
Disclosery

Vestal Point Capital, LP

Follow

13F filer, CIK 1974915, NEW YORK, NY

Vestal Point Capital, LP reported $4,279,457,817 across 68 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 50.29% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001974915-26-000005

Period
2026-06-30
Reported value
$4.28B
Holdings
68
Top 10 weight
50.29%
New
11
Sold out
33

Largest buys vs the previous quarter

SecurityShares changeApprox. value
UTHRadded+360,000$195M
BMRNadded+2,450,000$140M
ABTnew+1,400,000$127M
ABVXadded+849,443$113M
NBIXadded+630,000$106M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RVMDreduced-1,925,000-$361M
APGEexited-1,100,000-$92.6M
ASNDexited-375,000-$85.8M
RGENreduced-525,000-$71.6M
SRRKexited-1,324,422-$65.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001974915-26-000005, largest first. % of portfolio is the value over $4,279,457,817, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 400,000 shares; 2024Q4: 860,000 shares; 2025Q1: not reported; 2025Q2: 500,000 shares; 2025Q3: 830,000 shares; 2025Q4: 3,000,000 shares; 2026Q1: 3,575,000 shares; 2026Q2: 6,025,000 shares 6,025,000$345M8.06%+2,450,000Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 30,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,250,000 shares; 2026Q2: 1,880,000 shares 1,880,000$317M7.4%+630,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000,000 shares; 2025Q4: 1,900,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 2,349,443 shares 2,349,443$313M7.32%+849,443Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 75,000 shares; 2026Q2: 435,000 shares 435,000$236M5.51%+360,000Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 250,000 shares; 2025Q3: 1,160,000 shares; 2025Q4: 3,830,000 shares; 2026Q1: 3,250,000 shares; 2026Q2: 4,000,000 shares 4,000,000$203M4.74%+750,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 425,000 shares; 2024Q4: 485,000 shares; 2025Q1: 1,125,552 shares; 2025Q2: 2,000,000 shares; 2025Q3: 3,475,000 shares; 2025Q4: 4,690,000 shares; 2026Q1: 6,500,000 shares; 2026Q2: 8,050,000 shares 8,050,000$195M4.56%+1,550,000Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 425,000 shares; 2024Q4: 710,000 shares; 2025Q1: 2,768,975 shares; 2025Q2: 5,000,000 shares; 2025Q3: 5,100,000 shares; 2025Q4: 3,575,000 shares; 2026Q1: 5,425,000 shares; 2026Q2: 5,250,000 shares 5,250,000$156M3.64%-175,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,000,000 shares; 2025Q3: 5,500,000 shares; 2025Q4: 13,750,000 shares; 2026Q1: 18,000,000 shares; 2026Q2: 19,415,000 shares 19,415,000$132M3.09%+1,415,000Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 900,000 shares; 2026Q1: 2,275,000 shares; 2026Q2: 1,575,000 shares 1,575,000$128M3%-700,000Timeline
ABTABBOTT LABORATORIESQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 175,000 shares; 2025Q3: 250,000 shares; 2025Q4: 600,000 shares; 2026Q1: not reported; 2026Q2: 1,400,000 shares 1,400,000$127M2.97%newTimeline
ZBHZIMMER BIOMET HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 50,000 shares; 2025Q3: not reported; 2025Q4: 150,000 shares; 2026Q1: 190,000 shares; 2026Q2: 1,400,000 shares 1,400,000$121M2.82%+1,210,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 140,000 shares; 2025Q3: 500,000 shares; 2025Q4: 735,000 shares; 2026Q1: 700,000 shares; 2026Q2: 1,550,000 shares 1,550,000$113M2.65%+850,000Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 930,000 shares; 2024Q4: 425,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 800,000 shares; 2025Q4: 775,000 shares; 2026Q1: 3,603,465 shares; 2026Q2: 4,600,000 shares 4,600,000$111M2.6%+996,535Timeline
PODDINSULET CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,601 shares; 2026Q2: 670,000 shares 670,000$102M2.38%+619,399Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 375,000 shares 375,000$100M2.34%newTimeline
AZNASTRAZENECA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 100,000 shares; 2026Q2: 450,000 shares 450,000$85.3M1.99%+350,000Timeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 150,000 shares; 2024Q4: 750,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,400,000 shares; 2026Q2: 2,000,000 shares 2,000,000$85.3M1.99%+600,000Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,200,000 shares; 2025Q3: 630,000 shares; 2025Q4: 295,000 shares; 2026Q1: 2,375,000 shares; 2026Q2: 450,000 shares 450,000$84.3M1.97%-1,925,000Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,250,000 shares; 2026Q1: 7,025,000 shares; 2026Q2: 8,300,000 shares 8,300,000$83M1.94%+1,275,000Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,800,000 shares; 2025Q2: 727,500 shares; 2025Q3: 2,775,000 shares; 2025Q4: 120,000 shares; 2026Q1: 4,000,000 shares; 2026Q2: 3,375,000 shares 3,375,000$75M1.75%-625,000Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 285,000 shares; 2026Q2: 1,000,000 shares 1,000,000$69.8M1.63%+715,000Timeline
GMEDGLOBUS MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 325,000 shares; 2025Q1: 200,000 shares; 2025Q2: 500,000 shares; 2025Q3: 1,250,000 shares; 2025Q4: 1,275,000 shares; 2026Q1: 610,520 shares; 2026Q2: 850,000 shares 850,000$67.2M1.57%+239,480Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 230,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares; 2026Q2: 1,050,000 shares 1,050,000$66.1M1.54%+850,000Timeline
IMTXIMMATICS N.VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,750,000 shares; 2024Q4: 6,275,000 shares; 2025Q1: 7,192,700 shares; 2025Q2: 6,250,000 shares; 2025Q3: 6,350,000 shares; 2025Q4: 6,125,000 shares; 2026Q1: 6,175,000 shares; 2026Q2: 6,175,000 shares 6,175,000$62.6M1.46%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,166,504 shares; 2026Q2: 3,100,000 shares 3,100,000$57.8M1.35%+933,496Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 585,000 shares; 2026Q1: 2,766,868 shares; 2026Q2: 1,800,000 shares 1,800,000$57.1M1.34%-966,868Timeline
RGENREPLIGEN CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 400,000 shares; 2025Q4: 83,000 shares; 2026Q1: 925,000 shares; 2026Q2: 400,000 shares 400,000$54.6M1.28%-525,000Timeline
BMYBRISTOL-MYERS SQUIBB COQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 250,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 250,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 800,000 shares 800,000$46.1M1.08%-200,000Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,750,000 shares; 2024Q4: 3,025,000 shares; 2025Q1: 4,792,572 shares; 2025Q2: 3,700,000 shares; 2025Q3: 225,000 shares; 2025Q4: not reported; 2026Q1: 358,996 shares; 2026Q2: 935,000 shares 935,000$43.1M1.01%+576,004Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 825,000 shares; 2024Q4: 810,000 shares; 2025Q1: 1,300,000 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,100,000 shares; 2025Q4: 600,000 shares; 2026Q1: 639,900 shares; 2026Q2: 700,000 shares 700,000$42.3M0.99%+60,100Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 492,319 shares; 2026Q2: 545,000 shares 545,000$38.3M0.89%+52,681Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 30,000 shares; 2024Q4: 95,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 31,468 shares; 2026Q2: 65,000 shares 65,000$34.9M0.82%+33,532Timeline
ALCALCON AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 525,000 shares; 2025Q3: 1,100,000 shares; 2025Q4: 1,105,000 shares; 2026Q1: 800,000 shares; 2026Q2: 500,000 shares 500,000$33.5M0.78%-300,000Timeline
MYGNMYRIAD GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 600,000 shares; 2025Q4: 1,223,000 shares; 2026Q1: 1,648,000 shares; 2026Q2: 5,735,000 shares 5,735,000$32.7M0.77%+4,087,000Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 950,000 shares; 2025Q4: 1,110,000 shares; 2026Q1: 1,436,229 shares; 2026Q2: 730,000 shares 730,000$30.4M0.71%-706,229Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 1,630,000 shares 1,630,000$29.3M0.69%+130,000Timeline
GEHCGE HEALTHCARE TECHNOLOGIES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 204,130 shares; 2025Q2: 700,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares; 2026Q2: 450,000 shares 450,000$28.8M0.67%+200,000Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,600,000 shares; 2024Q4: 900,000 shares; 2025Q1: 1,075,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 250,000 shares 250,000$26.7M0.62%newTimeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 914,147 shares; 2026Q2: 680,000 shares 680,000$26.5M0.62%-234,147Timeline
BBNXBETA BIONICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 550,000 shares; 2025Q3: 600,000 shares; 2025Q4: 600,000 shares; 2026Q1: 2,211,518 shares; 2026Q2: 1,600,000 shares 1,600,000$25.1M0.59%-611,518Timeline
REGNREGENERON PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 20,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 25,000 shares; 2025Q4: not reported; 2026Q1: 40,000 shares; 2026Q2: 40,000 shares 40,000$24.9M0.58%0Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,800,000 shares; 2024Q4: 2,850,000 shares; 2025Q1: 1,753,558 shares; 2025Q2: 1,505,000 shares; 2025Q3: 2,975,000 shares; 2025Q4: 5,815,000 shares; 2026Q1: 5,000,000 shares; 2026Q2: 2,160,000 shares 2,160,000$21.6M0.5%-2,840,000Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 650,000 shares; 2024Q4: 915,000 shares; 2025Q1: 915,000 shares; 2025Q2: 950,000 shares; 2025Q3: 950,000 shares; 2025Q4: 2,485,000 shares; 2026Q1: 2,064,075 shares; 2026Q2: 785,000 shares 785,000$20.7M0.48%-1,279,075Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,013,000 shares 1,013,000$20.4M0.48%newTimeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 850,000 shares; 2024Q4: 1,200,000 shares; 2025Q1: 1,136,249 shares; 2025Q2: 3,228,161 shares; 2025Q3: 3,250,000 shares; 2025Q4: 4,475,000 shares; 2026Q1: 4,475,000 shares; 2026Q2: 4,320,000 shares 4,320,000$20.1M0.47%-155,000Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,090,000 shares; 2024Q4: 10,775,000 shares; 2025Q1: 11,000,000 shares; 2025Q2: 11,015,000 shares; 2025Q3: 4,015,000 shares; 2025Q4: 1,606,000 shares; 2026Q1: 2,600,052 shares; 2026Q2: 2,720,000 shares 2,720,000$16.8M0.39%+119,948Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 600,000 shares; 2026Q2: 575,000 shares 575,000$15M0.35%-25,000Timeline
SGPSPYGLASS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 666,760 shares; 2026Q2: 670,000 shares 670,000$14.9M0.35%+3,240Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 328,000 shares; 2026Q1: 328,000 shares; 2026Q2: 425,000 shares 425,000$14.6M0.34%+97,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 775,000 shares 775,000$14.3M0.33%newTimeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,000,000 shares 1,000,000$13.3M0.31%newTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 575,000 shares 575,000$12.7M0.3%newTimeline
AVRANTERIS TECHNOLOGIES GLOBALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,144,780 shares; 2026Q2: 1,010,000 shares 1,010,000$9.95M0.23%-134,780Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares; 2026Q2: 365,000 shares 365,000$9.26M0.22%+165,000Timeline
VYGRVOYAGER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 490,000 shares; 2024Q4: 1,230,000 shares; 2025Q1: 1,249,418 shares; 2025Q2: 1,475,000 shares; 2025Q3: 1,475,000 shares; 2025Q4: 1,475,000 shares; 2026Q1: 3,002,936 shares; 2026Q2: 2,625,000 shares 2,625,000$9.19M0.21%-377,936Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 635,000 shares; 2025Q1: 635,000 shares; 2025Q2: 635,000 shares; 2025Q3: 635,000 shares; 2025Q4: 635,000 shares; 2026Q1: 1,839,819 shares; 2026Q2: 1,825,699 shares 1,825,699$8.33M0.19%-14,120Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 338,611 shares; 2026Q2: 304,669 shares 304,669$7.91M0.18%-33,942Timeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 65,418 shares; 2026Q2: 75,727 shares 75,727$7.01M0.16%+10,309Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 511,000 shares; 2026Q2: 1,173,956 shares 1,173,956$6.93M0.16%+662,956Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,650,000 shares; 2026Q1: 428,551 shares; 2026Q2: 418,551 shares 418,551$5.24M0.12%-10,000Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,500,000 shares; 2026Q2: 2,500,000 shares 2,500,000$5.22M0.12%0Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,600,000 shares 2,600,000$4.55M0.11%newTimeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 535,452 shares 535,452$4.14M0.1%newTimeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,667,430 shares 1,667,430$2.88M0.07%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,686,000 shares; 2026Q1: not reported; 2026Q2: 382,999 shares 382,999$1.99M0.05%newTimeline
NYXHNYXOAH S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 2,924,216 shares; 2025Q1: 2,318,954 shares; 2025Q2: 1,402,002 shares; 2025Q3: 1,107,413 shares; 2025Q4: 1,107,000 shares; 2026Q1: 868,661 shares; 2026Q2: 843,461 shares 843,461$1.43M0.03%-25,200Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 83,333 shares; 2024Q4: 55,189 shares; 2025Q1: 53,439 shares; 2025Q2: 53,439 shares; 2025Q3: 53,439 shares; 2025Q4: 53,439 shares; 2026Q1: 53,439 shares; 2026Q2: 53,439 shares 53,439$778K0.02%0Timeline
APREAPREA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares; 2026Q2: 350,000 shares 350,000$281K0.01%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
APGEAPOGEE THERAPEUTICS INC1,100,000$92.6Mshares
ASNDASCENDIS PHARMA A/S375,000$85.8Mshares
SRRKSCHOLAR ROCK HLDG CORP1,324,422$65.1Mshares
VERAVERA THERAPEUTICS INC1,368,159$55Mshares
TERNTERNS PHARMACEUTICALS INC1,000,000$52.7Mshares
BSXBOSTON SCIENTIFIC CORP800,000$50.2Mshares
NUVLNUVALENT INC481,715$49.4Mshares
COGTCOGENT BIOSCIENCES INC1,230,888$47.4Mshares
CLDXCELLDEX THERAPEUTICS INC NEW1,224,165$38.8Mshares
KALVKALVISTA PHARMACEUTICALS INC1,850,000$37.2Mshares
PTGXPROTAGONIST THERAPEUTICS INC326,159$34.4Mshares
DNLIDENALI THERAPEUTICS INC1,773,326$34Mshares
WATWATERS CORP100,000$29.8Mshares
INSPINSPIRE MED SYS INC539,269$27.8Mshares
SLNOSOLENO THERAPEUTICS INC730,000$24.4Mshares
CYTKCYTOKINETICS INC300,000$19.8Mshares
WSTWEST PHARMACEUTICAL SVSC INC75,000$18.8Mshares
WGSGENEDX HOLDINGS CORP250,000$16.1Mshares
AGIOAGIOS PHARMACEUTICALS INC450,000$15.2Mshares
ENGNENGENE HOLDINGS INC2,165,000$14.7Mshares
ARVNARVINAS INC905,465$9.6Mshares
MPLTMAPLIGHT THERAPEUTICS INC420,000$8.54Mshares
FULCFULCRUM THERAPEUTICS INC1,100,000$8.44Mshares
CADLCANDEL THERAPEUTICS INC1,125,000$5.51Mshares
VCYTVERACYTE INC130,687$4.21Mshares
GERNGERON CORP2,540,000$3.78Mshares
NVCRNOVOCURE LTD250,000$2.73Mshares
URGNUROGEN PHARMA LTD139,079$2.5Mshares
PASGPASSAGE BIO INC305,000$2.39Mshares
TYRATYRA BIOSCIENCES INC54,000$2.07Mshares
RGNXREGENXBIO INC108,525$909Kshares
MGNXMACROGENICS INC280,000$809Kshares
ABSIABSCI CORPORATION232,219$697Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001974915-26-000005 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001974915-26-000005 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001974915-26-000004 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001974915-26-000002 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001974915-25-000008 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001974915-25-000006 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001974915-25-000005 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001974915-25-000002 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001974915-24-000011 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001974915-24-000006 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001974915-24-000005 Quarter ended 2024-03-312024-05-14acceptance time not in the bulk data set
13F-HR 0001974915-24-000002 Quarter ended 2023-12-312024-02-13acceptance time not in the bulk data set